This study aimed to investigate the association between longitudinal exposure to mycophenolic acid (MPA) and acute rejection (AR) risk in the first year after renal transplantation, and to propose MPA exposure targets conditionally to this association. A joint model, adjusted for monitoring strategy (fixed-dose versus concentration-controlled) and recipient age, was developed; it combined a mixed-effects model to describe the whole Using a new modeling approach which recognizes the repeated measures in a same patient, this study supports the association between MPA exposure and AR.
Introduction
Mycophenolate mofetil (MMF) is an ester prodrug of the immunosuppressant mycophenolic acid (MPA) indicated in combination with cyclosporine (CsA) or tacrolimus to prevent rejection following organ transplantation.
The role of therapeutic drug monitoring (TDM) for MPA is still debated by many physicians, and the controversies of its utility were recently discussed (1, 2) .
Several observational studies comparing, over the first year post-transplantation, patients with and without T-cell mediated acute rejection (AR) found lower MPA inter-dose area under the plasma concentration vs. time curve (AUC) values in patients with AR (3) (4) (5) . However, a few other observational studies did not detect such an association between MPA AUC and rejection (6) (7) (8) . The association between MPA AUC and the risk of rejection has also been investigated in a few randomized controlled trials (RCTs), providing a higher level of evidence than observational retrospective studies (9, 10) . However, their results were also discordant. The Randomized Concentration Control Trial -RCCT-study (11) compared, in renal-transplant patients co-treated with MMF and CsA, the incidence of AR in three patient groups assigned to low (MPA AUC 0-12h <30 mg.h/L), intermediate (AUC 0-12h = 30 to 60 mg.h/L) or high (AUC 0-12h >60 mg.h/L) MPA exposure. This trial showed a significantly higher incidence of AR in the low MPA exposure group and an increased incidence of adverse effects with no gain in efficacy in the higher exposure group, as compared to the intermediate group. Consequently, a 30-60 mg.h/L target window was proposed for MPA AUC 0-12h . Two prospective randomized trials (the so-called APOMYGRE (12) and FDCC (13) studies) further compared the incidence of AR in patients receiving, over the first year post-transplantation, either a fixed-dose (FD) regimen of MMF (1g twice daily in adults) or a concentration-controlled (CC) regimen adjusted to achieve a target MPA AUC 0-12h (of 45 and 40 mg.h/L in FDCC and APOMYGRE, respectively). The FDCC study (13) and pediatric patients co-treated with CsA or tacrolimus, allowed for different analytical methods for MPA measurement, employed multiple linear regression for AUC estimation and let clinicians calculate the adjusted doses. It did not show any difference between the two randomization groups. However, retrospective analysis of the concentration-effect data showed a significant association between early MPA AUC (i.e., on day 3) and biopsy proven AR occurring in the first month, as well as in the first year post-transplantation. More specifically, a recent re-analysis of the FDCC data showed that this statistical association was only true in high-risk patients (i.e., patients with one or more of the following characteristics: delayed graft function, second or third transplantation, panel reactive antibodies >15%, four or more human leukocyte antigen mismatches, or of black race) (14) . In the APOMYGRE study (12) , only adult patients co-treated with CsA were enrolled, MPA measurements were performed by high-performance liquid chromatography (HPLC), AUC were calculated by Bayesian estimation (15) and dose adjustments were computer-assisted. The median MPA AUCs were higher in the CC group at day 14 and at month 1, a time at which significantly more patients had AUC values above the target of 40 mg.h/L. A significantly higher incidence of AR was found in the FD group compared to the CC group (Cox model, p=0.017).
Interestingly, there was no AR episode associated with an AUC >45 mg.h/L in the first three months post-transplantation. The last randomized fixed-dose vs. concentration-controlled trial in patients with a low immunologic risk (OPERA) (16) failed to demonstrate the benefit of MPA TDM: at 12 months, the overall rejection rates were similar in both groups.
One explanation of these discrepant results might be the insufficient statistical power of some of these RCTs. As we previously highlighted (17) , the feasibility of such a study depends upon: (i) compliance with the pharmacokinetic sampling time-windows; (ii) use of relevant tools for accurate drug exposure estimation and dose adjustment calculation; and (iii) good compliance of the physicians with regard to the recommended doses. One of the problems inserm-00809389, version 1 -9 Apr 2013 inserm-00809389, version 1 -9 Apr 2013 with the FDCC trial (13) was probably that the proposed changes in MMF dose were not always appropriate, and were not performed in more than half of the cases.
Anyway, several recent consensus conferences (18) (19) (20) have recommended MMF monitoring based on MPA AUC in renal-transplant patients, mainly to overcome the problems of interpatient variability and time-dependent variations of MPA pharmacokinetics. Currently, MPA AUC is repeatedly measured in quite a number of transplantation centers (21) .
No retrospective study dealing with MMF has taken into account the drug exposure profiles over time in order to analyze the longitudinal exposure/efficacy relationship and determine optimized exposure target values for TDM. The so-called "joint" or "time-to-event" models can now be used to conduct such pharmacokinetic/pharmacodynamic (PK/PD) studies. These models were recently proposed in the biostatistics area (22) (23) (24) (25) to analyze simultaneously a longitudinal outcome, such as the repeated measurement of a biomarker (e.g., the MPA AUC measured at different times after transplantation), and a survival outcome which is the time to an event of interest (e.g., AR). At this time, only one study dealing with an immunosuppressive drug (Belatacept) has reported a joint model to analyze the relationship between time-varying exposure and AR; but no significant association was found (26) .
Additionally, receiver-operating characteristics (ROC) curves specifically adapted to joint models have also been developed and validated; this allows calculating time-dependent threshold values for a time-dependent explanatory variable (27) .
The aims of the present study were to: (i) analyze the relationship between longitudinal exposure to MPA and AR in the first year following renal transplantation using a joint model; and (ii) to determine time-dependent MPA AUC thresholds in order to minimize the risk of rejection.
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Materials and methods

Patients and treatment
Data were collected from the databases of two multicenter, randomized clinical trials intended to investigate the clinical impact of MMF TDM in renal-transplant recipients, namely APOMYGRE (NCT0019967) and OPERA, and from adult renal-transplant recipients transplanted between 2007 and 2011 and routinely followed up at Limoges University Hospital. The trials complied with the Declaration of Helsinki. APOMYGRE was approved by the regional ethics committee of Limoges, France; OPERA was approved by the Independent Ethics Committee and by the relevant authorities (EUDRACT 2006-000352-41).
All patients were followed during the first 12 months post-transplantation ( Table 1 ). The different immunosuppressive regimens employed are reported in Table 2 . In APOMYGRE and OPERA studies, patients were randomly divided (1:1) into two groups to receive concentration-controlled (CC) or fixed-dose (FD) of MMF. All patients received antibody induction therapy (basiliximab, daclizumab, or thymoglobuline) in conjunction with dual or triple maintenance therapy consisting in a starting dose of 1g MMF twice daily associated to a calcineurin inhibitor (CNI) (i.e., CsA for APOMYGRE and OPERA patients as well as for 41 routinely followed patients or tacrolimus for 100 routinely followed patients) and/or corticosteroids. All patients enrolled in OPERA were considered at low immunological risk.
Study endpoints
The joint models were used to model a longitudinal explanatory variable and a time-to-event explained process, simultaneously. Herein, the two endpoints considered were: (i) repeated (15) . MPA AUC values were studied for each patient at different time periods within the first year post-transplantation (the visit times planned in each study are reported in Table 1 ) except for 7 patients who experienced AR within the first month post-transplantation (i.e 2, 1 and 4 patients with AR around W1, W2 and M1, respectively). For these 7 patients for whom a single MPA AUC measurement was available, the single observed MPA AUC was duplicated one day after in order to keep these patients in the analysis. On the other hand, patients, who did not experience AR and with a single available MPA AUC value, were excluded from the analysis (i.e., 26 patients from the OPERA study and 2 patients from the APOMYGRE trial). In total, 221 patients included in OPERA, 128 in APOMYGRE and 141 patients routinely followed at Limoges were studied herein. Among these 490 MPA AUC trajectories provided, 56 were made up of only two MPA AUC values due to either occurrence of AR within the three first months post-transplantation (n=26) or non-compliance with the schedule of measurement of MPA AUC (n=30). In this later situation, patients were censored at the last examination time. episode in the first year post-transplantation. All were proven by histological reading of the renal biopsy except three (who were included in the APOMYGRE study) due to coadministration of anticoagulants which is a contra-indication. Figure 2 summarizes the important steps taken in the modeling framework which are described here.
Modeling framework
Development of a joint model between longitudinal MPA exposure and the risk of AR
A brief technical specification of the joint models for longitudinal and survival data that we employed is presented in the Supplementary Material and Methods online, but the intention behind it can be described with the following three-step procedure.
In the first step, the individual trajectories of MPA AUC time-course obtained from the repeated estimates of AUCs collected in the first year post-transplantation (i.e., the longitudinal explanatory variable) are fitted using a mixed-effects model. Time was tested as a fixed-effect variable. Random effects were used to describe the inter-patient variability.
In the second step, rejection-free survival was studied using a time-dependent relative risk model with a Weibull baseline risk function. As the incidence of AR is known to decrease with time, the Weibull survival distribution was assessed to describe the time-dependent decrease in the hazard function (29) .
The recipient age, the associated CNI, the "study" provenance (i.e., APOMYGRE/OPERA/ routinely followed patients) and the MMF dose-adjustment (DA) strategy used (namely FD and CC) were tested as covariates both in the mixed-effects sub-model (which describes the trajectories of MPA AUC) as well as in the survival sub-model. A covariate was retained in the model if its inclusion improved the log-likelihood significantly (p<0.05).
In the third step, the mixed-effects model selected to describe the time course of MPA AUC was incorporated in the survival model. The resulting joint model allowed measuring the inserm-00809389, version 1 -9 Apr 2013 inserm-00809389, version 1 -9 Apr 2013 strength of the association between MPA longitudinal exposure and the hazard for AR. The goodness-of-fit of the final joint model was checked using classically recommended diagnostic plots based on: (i) the marginal and subject-specific residuals for the longitudinal outcome; and (ii) the martingale and Cox-Snell residuals for the time-to-event outcome. The Cox-Snell residuals were calculated as the value of the cumulative risk function evaluated at the times when the event occurred. The Cox-Snell residuals plot is expected to have a unit exponential distribution (30) . The software implementation of these joint models is the JM-Rpackage described by Rizopoulos et al (22) .
Internal model validation
The accuracy and robustness of the joint model were assessed by an internal validation, using a non-parametric bootstrap method. Briefly, 300 bootstrap sets were obtained by resampling from the original dataset, each providing estimates of model parameters. The small number of bootstrap datasets used is due to long computational times. The mean and 95% confidence interval values of each model parameter estimated from the 300 bootstrap sets were compared to the corresponding parameters obtained with the original dataset. This procedure was performed using the R software version 2.13.0 (R foundation for statistical computing, http://www.r-project.org).
Determination of time-dependent targets of MPA exposure for individual dose adjustment.
This step aims to determine the target exposure levels minimizing the risk of AR.
We estimated time-dependent thresholds (i.e., time-varying cut-offs) of MPA exposure using time-dependent ROC curves adapted to a joint modeling framework (27) . Traditional ROC analysis assumes that the explanatory variable does not change over time, which is the case when its measurement is performed once, at the time of diagnostic. Herein, the exposure to MPA varied over time and AR could occur during the course of the patient follow-up. The inserm-00809389, version 1 -9 Apr 2013 inserm-00809389, version 1 -9 Apr 2013 time-dependent ROC curves used herein allowed the determination of threshold values that evolve over time. Thus, a different MPA AUC threshold for each post-transplantation studied period (days 7-14 and months 1, 3, and 6 post-transplantation) was determined by taking into account the shape of the MPA AUC time patterns. The 300 bootstrap samples used for the internal model validation were also used to determine the non-parametric 95% intervals of the ROC thresholds (defined by the 2.5 th and 97.5 th percentiles of the thresholds).
Results
Joint model for longitudinal MPA exposure and the risk of AR in the training dataset.
A polynomial function with a quadratic term was selected to describe the trajectories of MPA AUCs over time. A significant improvement was obtained by inclusion of the MMF doseadjustment strategy as covariate in the model (i.e., fixed-dose vs concentration-controlled).
The survival model was adjusted to the recipient age. The final longitudinal and survival submodels obtained were expressed in the equations (1) and (2), respectively.
(1) Y i (t ij ) = β 0 + β 1 x tij + β 2 x t ij 2 + β 3 
Where:
in ( Table 3 .
The residual plots, performed to check the goodness of fit of the joint model, are illustrated in Figure 3 . The fitted loess curves in the plots of the standardized marginal and subject-specific residuals did not show any systematic error trend. Also, no systematic error trend was observed for the martingale residuals, indicating that the formulation chosen to describe the MPA AUC profiles was appropriate (30) . Moreover, the unit exponential distribution seemed to be very close to the Kaplan-Meier estimates of the Cox-Snell residuals, and well within the 95% confidence interval (CI), indicating a good fitting of the survival part of the joint model.
Two hundred eighty seven out of 300 runs converged successfully in the bootstrap analysis.
The mean bootstrap parameter estimates and their 95% confidence intervals are shown in Table 3 . The mean of the bootstrap parameters was not statistically different from the parameter estimates based on the original dataset ( 
Discussion
Our study showed, in a large group of patients, a significant association between longitudinal exposure to MPA and the incidence of AR over the first year post-transplantation. Joint models offer an efficient method to quantify the risk of AR linked to a longitudinal marker of exposure such as the MPA AUCs. Indeed, by relying on the individual longitudinal exposure, these models account for the intra-patient pharmacokinetic variability (22) (23) (24) (25) . In this study, the joint model used included a polynomial mixed-effects sub-model to describe the longitudinal evolution of MPA AUCs and a Weibull survival sub-model for the hazard of AR. The model was improved by introducing the MMF dose-adjustment (DA) strategy and the recipient age as covariates in the longitudinal and survival sub-models respectively. We found a significant association between MPA exposure and AR in the first year after transplantation. The classic diagnostic plots used (30) revealed that this model had no major bias and fitted the survival data well. Interestingly, the association between MPA exposure and AR remained statistically significant (p=0.0466) when the re-transplanted patients (n=14)
were excluded from the database. This shows that the association also exists when only de novo renal-transplant patients are considered. Additionally, the database was re-analyzed after exclusion of the patients included in OPERA which was a study done in a population at low risk for acute rejection. The incidence of acute rejection was lower in OPERA than in the rest Hest et al (34) found that the time-dependent change of exposure to MPA is caused by decreasing apparent clearance of MPA, due to a combination of improving creatinine clearance, increasing albumin, increasing haemoglobin and decreasing CsA predose concentrations during the first 6 months after transplantation. On the other hand, in the present study, as recommended, the shorter the interval after transplantation, the higher the target concentrations used for cyclosporine (35) and tacrolimus (36) were. This should help justify the use of lower target MPA exposures to adjust the immunosuppression level.
According to the MPA thresholds proposed in our study, more than half of the patients were underexposed in the very first weeks post-transplantation (e.g., 61.4% of AUCs were less than 30 mg.h/L at week 2). This result is in accordance with previous studies (12, 14) . Interestingly, in the CC sub-group, patients achieved the therapeutic target exposure faster than in the FD sub-group: only 30.4% had a MPA exposure less than 30 mg.h/L at week 2. However, the proportion of underexposed patients in both sub-groups decreased over time: 30.4% and 
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Supplementary Material and Methods
The joint model framework used in this study has been described by Rizopoulos et al (1) and can be formulated briefly in the following 3 steps:
 The longitudinal sub-model
The "true unobserved" (i.e., theoretical) trajectory of the biomarker is described by a mixedeffects model which can be expressed as: Where:
 h 0 (t) is the baseline risk function. Several different options including both parametric (i.e., Weibull, piecewise-constant, B-splines) or semi-parametric (i.e., Cox) models are available for h 0 (t) in the JM package.
 M i (t) = { m i (s), 0≤s<t} denotes the theoretical, unobserved biomarker history up to time t. The true trajectory of the biomarker at time t (m i (t)) is obtained using the mixedeffects longitudinal sub-model described above.
 α quantifies the effect of the biomarker on the hazard for the event. It measures the strength of the association between m i (t) that denotes the true level of the biomarker at time t, and the hazard for an event at the same time point.
 W i is a vector of baseline covariates (such as a treatment indicator, age …) with a corresponding vector of regression coefficients γ.
 The joint model
The two processes (survival sub-model and longitudinal sub-model) are combined using joint log-likelihood estimation. This joint distribution between the two processes assumes that both sub-models share the same random effects (conditional independence assumptions).
In order to fit the joint model, the objects returned by the mixed-effects sub-model and the survival sub-model were used as the main arguments in the joint model, also called "time to event model". The Gauss Hermite integration rule was used for the maximization of the joint log-likelihood function. 
